Reported Earnings • Apr 16
Full year 2024 earnings released: EPS: S$0.033 (vs S$0.024 in FY 2023) Full year 2024 results: EPS: S$0.033 (up from S$0.024 in FY 2023). Revenue: S$78.2m (down 6.7% from FY 2023). Net income: S$43.8m (up 36% from FY 2023). Profit margin: 56% (up from 38% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Apr 14
TalkMed Group Limited, Annual General Meeting, Apr 29, 2025 TalkMed Group Limited, Annual General Meeting, Apr 29, 2025, at 18:00 Singapore Standard Time. Location: hotel royal, 36 newton road, singapore 307964, Singapore Reported Earnings • Feb 26
Full year 2024 earnings released Full year 2024 results: Revenue: S$84.1m (flat on FY 2023). Net income: S$43.8m (up 36% from FY 2023). Profit margin: 52% (up from 38% in FY 2023). New Risk • Jan 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Dividend is not well covered by earnings (103% payout ratio). Announcement • Dec 25
Tamarind Health Limited entered into an implementation agreement to acquire TalkMed Group Limited (SGX:5G3) from Ladyhill Holdings Pte. Ltd.,Ang Peng Tiam, Khoo Kei Siong, Lim Hong Liang and Teo Cheng Peng for approximately SGD 600 million. Tamarind Health Limited entered into an implementation agreement to acquire TalkMed Group Limited (SGX:5G3) from Ladyhill Holdings Pte. Ltd.,Ang Peng Tiam, Khoo Kei Siong, Lim Hong Liang and Teo Cheng Peng for approximately SGD 600 million on December 22, 2024. A cash consideration valued at SGD 0.456 per share will be paid by Tamarind Health Limited. As part of consideration, SGD 606.08 million is paid towards common equity of TalkMed Group Limited. As part of the deal, Teo Cheng Peng, Ang Peng Tiam, Khoo Kei Siong and Lim Hong Liang will undertake to reinvest In case of termination of transaction, seller will pay a termination fee of 6.10% or 1%. The transaction is subject to approval by regulatory board / committee, approval of offer by target shareholders, subject to court approval and Accounting and Corporate Regulatory Authority of Singapore lodgment. United Overseas Bank Limited acted as financial advisor for Tamarind Health Limited. Upcoming Dividend • Aug 07
Upcoming dividend of S$0.023 per share Eligible shareholders must have bought the stock before 14 August 2024. Payment date: 22 August 2024. The company is paying out more than 100% of its profits and is paying out 87% of its cash flow. Trailing yield: 5.6%. Lower than top quartile of Singaporean dividend payers (6.5%). Higher than average of industry peers (2.7%). Reported Earnings • Jul 18
First half 2024 earnings released: EPS: S$0.006 (vs S$0.009 in 1H 2023) First half 2024 results: EPS: S$0.006 (down from S$0.009 in 1H 2023). Revenue: S$33.1m (down 12% from 1H 2023). Net income: S$8.61m (down 31% from 1H 2023). Profit margin: 26% (down from 33% in 1H 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Declared Dividend • Jul 17
First half dividend of S$0.023 announced Shareholders will receive a dividend of S$0.023. Ex-date: 14th August 2024 Payment date: 22nd August 2024 Dividend yield will be 8.6%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is not adequately covered by earnings (91% earnings payout ratio). However, it is covered by cash flows (87% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share declined by 3.1% over the last 5 years, which if continued should see the payout ratio increase to a potentially unsustainable range. Upcoming Dividend • Apr 23
Upcoming dividend of S$0.013 per share Eligible shareholders must have bought the stock before 30 April 2024. Payment date: 10 May 2024. Payout ratio and cash payout ratio are on the higher end at 91% and 77% respectively. Trailing yield: 5.5%. Lower than top quartile of Singaporean dividend payers (6.3%). Higher than average of industry peers (2.5%). Announcement • Apr 19
TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023 TalkMed Group Limited at its Annual General Meeting held on 18 April 2024, approved final one-tier tax-exempt dividend of 1.30 Singapore cents per ordinary share in respect of the financial year ended 31 December 2023. Declared Dividend • Feb 22
Final dividend reduced to S$0.013 Dividend of S$0.013 is 13% lower than last year. Ex-date: 30th April 2024 Payment date: 10th May 2024 Dividend yield will be 5.8%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is not adequately covered by earnings (97% earnings payout ratio). However, it is covered by cash flows (78% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 7.9% to bring the payout ratio under control, which is more than the 2.0% EPS growth achieved over the last 5 years. Announcement • Feb 21
TalkMed Group Limited, Annual General Meeting, Apr 18, 2024 TalkMed Group Limited, Annual General Meeting, Apr 18, 2024. Agenda: To propose final dividend; and to consider other matters. Reported Earnings • Feb 21
Full year 2023 earnings released Full year 2023 results: Revenue: S$86.6m (up 13% from FY 2022). Net income: S$32.2m (up 5.3% from FY 2022). Profit margin: 37% (down from 40% in FY 2022). The decrease in margin was driven by higher expenses. Announcement • Feb 20
Talkmed Group Limited Proposes Tax Exempt (One-Tier) Final Dividend for the Financial Year Ended 31 December 2023, Payable on 10 May 2024 TalkMed Group Limited announced that shareholders to the tax exempt (one-tier) final dividend of 1.30 Singapore cents per ordinary share (the "Final Dividend") for the financial year ended 31 December 2023. Payment of the Final Dividend, if approved by the members at the Annual General Meeting to be held on 18 April 2024, will be made on 10 May 2024. Announcement • Nov 12
TalkMed Group Limited Announces Management Changes The board of directors of TalkMed Group Limited announced the following changes to the board and board committees of the company: The cessation of the following directors with effect from 31 December 2023: (a) Dr. Khoo Kei Siong, Executive Director; (b) Mr. Dan Yock Hian, Independent Non-Executive Director; (c) Mr. Lim Teong Jin George, Non-Independent Non-Executive Director; (d)Mr. Lim Jen Howe, Non-Independent Non-Executive Director. The appointment of the following new directors with effect from 1 January 2024: (a) Mr. Lam Kok Shang as an Independent Non-Executive Director of the Company, and Chairman of the Audit and Risk Committee and a member of the Nominating Committee; (b) Dr. Tan Khai Tong as an Independent Non-Executive Director of the Company, and a member of the Remuneration Committee; (c) Mr. Peter Sim Swee Yam as an Independent Non-Executive Director of the Company, and Chairman of Nominating Committee and a member of the Audit and Risk Committee. The re-designation of the following directors with effect from 1 January 2024: (a) Mr. S. Chandra Das as Non-Executive Director (from Independent Non-Executive Director) pursuant to Rule 210(5)(d)(iv) of the Listing Manual of the Singapore Exchange Securities Trading Limited (SG X-S T). Mr. S. Chandra Das will remain as Chairman of the Board and a member of the Remuneration Committee; (b) Mr. Sitoh Yih Pin as Non-Executive Director (from Independent Non-Executive Director) pursuant to Rule 210(5)(d)(iv) of the Listing Manual of the SGX-ST (Listing Manual). Mr. Sitoh Yih Pin will remain as a member of the Audit and Risk Committee; (c) Prof Leong Ching Ching as an Independent Non-Executive Director (from Non-Executive Director). Prof Leong will be appointed as Chairman of the Remuneration Committee. The appointment of Dr. Khoo Kei Siong as Alternate Director to Dr Ang Peng Tiam with effect from 1 January 2024. Dr Khoo will remain as the chief operating officer of the company upon his cessation as an executive director. Following the above changes, the composition of the board and the respective board committees is as follows: Audit and Risk Committee: Mr. Lam Kok Shang, Chairman; Mr. Sitoh Yih Pin, Member; Mr. Peter Sim Swee Yam, Member. Nominating Committee: Mr. Peter Sim Swee Yam, Chairman; Dr. Ang Peng Tiam, Member (Alternate: Dr Khoo Kei Siong); Mr. Lam Kok Shang, Member. Remuneration Committee: Prof Leong Ching Ching, Chairman; Mr. S. Chandra Das, Member; Dr. Tan Khai Tong, Member. Reported Earnings • Aug 08
First half 2023 earnings released: EPS: S$0.011 (vs S$0.009 in 1H 2022) First half 2023 results: EPS: S$0.011 (up from S$0.009 in 1H 2022). Revenue: S$37.8m (up 16% from 1H 2022). Net income: S$14.3m (up 18% from 1H 2022). Profit margin: 38% (in line with 1H 2022). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • May 17
TalkMed Group Limited Approves the Final One-Tier Tax-Exempt Dividend in Respect of 2022 The Board of TalkMed Group Limited had approved the a final one-tier tax-exempt dividend of 1.50 Singapore cents per ordinary share in respect of FY22, at the AGM held on 20 April 2023. Upcoming Dividend • Apr 21
Upcoming dividend of S$0.015 per share at 7.0% yield Eligible shareholders must have bought the stock before 28 April 2023. Payment date: 11 May 2023. The company is paying out more than 100% of its profits and is paying out 86% of its cash flow. Trailing yield: 7.0%. Within top quartile of Singaporean dividend payers (6.3%). Higher than average of industry peers (3.0%). Reported Earnings • Apr 06
Full year 2022 earnings released: EPS: S$0.023 (vs S$0.019 in FY 2021) Full year 2022 results: EPS: S$0.023 (up from S$0.019 in FY 2021). Net income: S$30.5m (up 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year. Reported Earnings • Feb 23
Full year 2022 earnings released Full year 2022 results: Revenue: S$77.8m (up 28% from FY 2021). Net income: S$30.5m (up 22% from FY 2021). Profit margin: 39% (down from 41% in FY 2021). The decrease in margin was driven by higher expenses. Board Change • Nov 28
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 7 highly experienced directors. Non-Independent Non-Executive Director Ching Ching Leong was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 03
TalkMed Group Limited Announces Tax Exempt (One-Tier) Interim Cash Dividend, Payable on 22 August 2022 The Share Transfer Books and Register of Members of TalkMed Group Limited will be closed at 5:00 p.m. on 12 August 2022 ("Record Date"), for the purpose of determining entitlements of ordinary shareholders to the tax exempt (one-tier) Interim Dividend of 1.50 Singapore cents per ordinary share (the "Interim Dividend") in respect of the financial year ending 31 December 2022. Duly completed registrable transfers received by the Company's Share Registrar, B.A.C.S. Private Limited at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, up to 5:00 p.m. on the Record Date will be registered before entitlements to the Interim Dividend are determined. Members whose securities accounts with The Central Depository (Pte) Limited are credited with the Company's ordinary shares as at 5:00 p.m. on the Record Date will be entitled to the Interim Dividend. Payment of the Interim Dividend will be made on 22 August 2022. Reported Earnings • Aug 03
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down S$10.8m from profit in 1H 2021). Profit margin: (down from 38% in 1H 2021). The decrease in margin was driven by lower expenses. Board Change • Jul 18
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 7 highly experienced directors. Non-Independent Non-Executive Director Ching Ching Leong was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 7 highly experienced directors. Non-Independent Non-Executive Director Ching Ching Leong was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 06
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: S$0.019 (up from S$0.017 in FY 2020). Net income: S$25.1m (up 10% from FY 2020). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates by 14%. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 9% per year. Announcement • Apr 04
TalkMed Group Limited, Annual General Meeting, Apr 21, 2022 TalkMed Group Limited, Annual General Meeting, Apr 21, 2022, at 18:00 Singapore Standard Time. Agenda: To receive and adopt the Directors' Statement and the Audited Financial Statements of the Company and the Group for the financial year ended 31 December 2021, together with the Auditor's Report thereon; to declare a final one-tier tax-exempt dividend of 0.90 Singapore cent per ordinary share in respect of the financial year ended 31 December 2021; to approve the payment of Directors' fees of SGD 500,000 for the financial year ending 31 December 2022 to be paid quarterly in arrears (2021: SGD 380,000); and to consider other matters. Board Change • Feb 25
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 7 highly experienced directors. Non-Independent Non-Executive Director Ching Ching Leong was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 17
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: S$62.7m (flat on FY 2020). Net income: S$25.1m (up 10% from FY 2020). Profit margin: 40% (up from 37% in FY 2020). Revenue exceeded analyst estimates by 8.8%. Announcement • Feb 16
TalkMed Group Limited Proposes Final Dividend, Payable on 11 May 2022 TalkMed Group Limited proposed final dividend at the Annual General Meeting to be held on 21 April 2022, the Share Transfer Books and Register of Members of the Company will be closed at 5:00 p.m. on 29 April 2022 ("Record Date"), for the purpose of determining entitlements of ordinary shareholders to the tax exempt (one-tier) final dividend of 0.90 Singapore cents per ordinary share. Payment of the Final Dividend, if approved by the members at the Annual General Meeting to be held on 21 April 2022, will be made on 11 May 2022. Executive Departure • Sep 07
Joint Company Secretary Lingna Dai has left the company On the 1st of September, Lingna Dai's tenure as Joint Company Secretary ended after 2.0 years in the role. We don't have any record of a personal shareholding under Lingna's name. Lingna is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 7.00 years. Is New 90 Day High Low • Mar 05
New 90-day low: S$0.40 The company is down 9.0% from its price of S$0.44 on 04 December 2020. The Singaporean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 41% over the same period. Announcement • Feb 19
TalkMed Group Limited, Annual General Meeting, Apr 20, 2021 TalkMed Group Limited, Annual General Meeting, Apr 20, 2021. Agenda: To consider approve the payment of the final dividend. Reported Earnings • Feb 19
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: S$65.0m (down 14% from FY 2019). Net income: S$22.8m (down 36% from FY 2019). Profit margin: 35% (down from 47% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Feb 19
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates by 14%. Over the next year, revenue is expected to shrink by 7.9% compared to a 5.9% growth forecast for the Healthcare industry in Singapore. Is New 90 Day High Low • Nov 12
New 90-day high: S$0.46 The company is up 7.0% from its price of S$0.42 on 13 August 2020. The Singaporean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 5.0% over the same period. Is New 90 Day High Low • Sep 21
New 90-day low: S$0.38 The company is down 11% from its price of S$0.42 on 23 June 2020. The Singaporean market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 9.0% over the same period.